Vulvovaginal Candidiasis Market

 Market Overview:

The 7 major vulvovaginal candidiasis markets reached a value of US$ 734.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,058.2 Million by 2034, exhibiting a growth rate (CAGR) of 3.37% during 2024-2034.

The vulvovaginal candidiasis market has been comprehensively analyzed in IMARC's new report titled "Vulvovaginal Candidiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vulvovaginal candidiasis, also referred to as vaginal yeast infection, is a fungal infection that is caused by an infestation of the fungus Candida in the vulva and vagina. The most common symptoms associated with the disease are itching, burning, and soreness in the vaginal area, as well as thick, white, odorless discharge. Various other indications include pain during sex or urination, redness and swelling of the vulva, general discomfort in the genital area, etc. In some cases, women may experience recurring infections or chronic symptoms that can significantly affect their quality of life. The diagnosis of this condition typically involves a physical examination by a healthcare provider, such as a pelvic exam and a swab of the vaginal discharge for testing. The laboratory tests include a microscopic examination or culture of the discharge to determine the presence of the fungus Candida, which is the primary cause of the ailment. Several other procedures may be performed to rule out potential causes of the indications, such as sexually transmitted infections or bacterial vaginosis.

The escalating usage of antibiotics, which results in the loss of beneficial bacteria that keep the vaginal ecosystem balanced, is primarily driving the vulvovaginal candidiasis market. In addition to this, the increasing incidences of several associated risk factors, including hormonal changes, weakened immune system, sexual relations with multiple partners, poor personal hygiene, etc., are further augmenting the market growth. Moreover, the emerging popularity of over-the-counter antifungal creams containing active ingredients, such as miconazole, clotrimazole, tioconazole, etc., to treat mild to moderate symptoms of the ailment is also creating a positive outlook for the market. Apart from this, the widespread adoption of probiotics as supplements or suppositories for restoring the natural balance of bacteria in the vaginal region is acting as another significant growth-inducing factor. Additionally, the ongoing advancements of molecular diagnostic methods that can detect Candida species with high sensitivity and specificity, are further bolstering the market growth. Besides this, the rising usage of non-pharmacological therapies, such as stress-reduction techniques and dietary modifications like reducing sugar intake to manage the disease symptoms is expected to drive the vulvovaginal candidiasis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the vulvovaginal candidiasis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for vulvovaginal candidiasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vulvovaginal candidiasis market in any manner.

Recent Developments:

• In February 2024, Sano Chemicals initiated its phase I, first-in-human clinical trial of Occidiofungin, a novel therapy for recurring vaginal yeast infections or vulvovaginal candidiasis. Occidiofungin is a fungicide that is being developed as a cure for infection rather than a suppressive medication.
• In January 2024, Hyloris Pharmaceuticals SA announced positive outcomes for the phase 2 trial of Miconazole Domiphen-Bromide (MCZ-DB) in individuals with acute vulvovaginal candidiasis. Both treatment arms with Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) showed excellent safety and tolerability.
• In March 2023, Scynexis secured an exclusive agreement with GSK for Brexafemme (ibrexafungerp), a US FDA-approved antifungal for the management of vaginal yeast infections and vulvovaginal candidiasis.

Key Highlights:

• Approximately 30-50% of women develop vulvovaginal candidiasis at least once throughout their lives.
• Women with diabetes are more likely to develop vulvovaginal candidiasis.
• In India, the prevalence of vulvovaginal candidiasis is 10–35%.
• Approximately 8% of women experience recurrent vulvovaginal candidiasis (more than three episodes annually).
• Recurrent vulvovaginal candidiasis rates increased with age, reaching 25% by 50 years.

Drugs:

BREXAFEMME is a triterpenoid antifungal that is used to treat adult and post-menarchal pediatric females with vulvovaginal candidiasis, as well as to reduce the occurrence of recurrent vulvovaginal candidiasis. Its method of action, glucan synthase inhibition, is fungicidal to Candida species, which means it kills fungal cells.

Prof-001 (Candiplus) is a novel, patent-protected medication for the local treatment of recurrent vaginal fungal infections. The therapeutic efficacy of the new combination medicine Candiplus is mediated by a completely novel mechanism based on the synergistic effects of the active ingredients.

MAT2203 is an oral and non-toxic encochleated version of amphotericin B (CAmB) developed using LNC technology. This antifungal medication is the principal broad-spectrum treatment for immunocompromised individuals. Unlike some other medicines, it doesn't just halt fungus from growing but eliminates it.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the vulvovaginal candidiasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the vulvovaginal candidiasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vulvovaginal candidiasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the vulvovaginal candidiasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the vulvovaginal candidiasis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the vulvovaginal candidiasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of vulvovaginal candidiasis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of vulvovaginal candidiasis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of vulvovaginal candidiasis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with vulvovaginal candidiasis across the seven major markets?
• What is the size of the vulvovaginal candidiasis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of vulvovaginal candidiasis?
• What will be the growth rate of patients across the seven major markets?
   

Vulvovaginal Candidiasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for vulvovaginal candidiasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vulvovaginal candidiasis market?
• What are the key regulatory events related to the vulvovaginal candidiasis market?
• What is the structure of clinical trial landscape by status related to the vulvovaginal candidiasis market?
• What is the structure of clinical trial landscape by phase related to the vulvovaginal candidiasis market?
• What is the structure of clinical trial landscape by route of administration related to the vulvovaginal candidiasis market?